Urologic oncology
Journal
Overview
publication venue for
-
Patient preferences for life expectancy cutoffs for aggressive treatment in clinically localized prostate cancer.
2024
-
The association between frailty, hypogonadism, and postoperative outcomes among men undergoing radical cystectomy.
2024
-
Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer..
41.
2023
-
Incidence and predictors of deep incisional and organ/space surgical site infection following radical cystectomy..
41.
2023
-
Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma..
41.
2023
-
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer..
40.
2022
-
A multidisciplinary approach to optimize primary prostate cancer biobanking.
2022
-
Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma.
2022
-
Does neoadjuvant chemotherapy diminish the sex disparity in bladder cancer survival after radical cystectomy?.
40.
2021
-
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma..
39.
2021
-
Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis..
39.
2021
-
Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder..
40.
2021
-
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02..
40.
2021
-
Prognostic significance of histomorphologic features of lymph node metastases in prostate cancer patients treated with radical prostatectomy: A single center study..
39.
2021
-
Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer..
39.
2021
-
Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer..
39.
2021
-
Tumor size and genomic risk in localized prostate cancer..
39.
2021
-
Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study..
39.
2021
-
Diagnostic yield of repeat evaluation for asymptomatic microscopic hematuria after negative initial workup..
39.
2020
-
Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter?.
39.
2020
-
A population-level analysis of nonsquamous penile cancer: The importance of histology..
39.
2020
-
The role of surgical experience in patient selection, surgical quality, and outcomes in robot-assisted radical cystectomy..
39.
2020
-
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab..
39.
2020
-
Preoperative nomogram predicting 12-year probability of metastatic renal cancer - evaluation in a contemporary cohort..
38.
2020
-
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival..
38.
2020
-
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer..
38.
2020
-
Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer..
39.
2020
-
Prognostic value of the SPOP mutant genomic subclass in prostate cancer..
38.
2020
-
The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma..
37.
2019
-
Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma..
37.
2019
-
Definitive and sustained increase in prostate cancer metastases in the United States..
37.
2019
-
Perioperative, oncological and functional outcomes after robotic partial nephrectomy vs. cryoablation in the elderly: A propensity score matched analysis..
37.
2019
-
Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy..
37.
2018
-
Robotic versus open partial nephrectomy for highly complex renal masses: Comparison of perioperative, functional, and oncological outcomes..
36.
2018
-
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations..
37.
2017
-
Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC)..
36.
2017
-
Concordance between patient-reported and physician-reported sexual function after radical prostatectomy..
36.
2017
-
Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes..
36.
2017
-
Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer..
35.
2017
-
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy..
35.
2017
-
Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma..
35.
2017
-
Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma..
35.
2016
-
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer..
34.
2016
-
Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer..
34.
2016
-
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer..
34.
2016
-
The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models..
35.
2016
-
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis..
34.
2016
-
GATA3 immunohistochemical expression in invasive urothelial carcinoma..
34.
2016
-
Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy..
34.
2016
-
The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm..
34.
2016
-
Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes..
34.
2015
-
Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design..
33.
2015
-
Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study..
33.
2015
-
BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study..
33.
2015
-
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)..
32.
2014
-
Adherence to surveillance guidelines after radical cystectomy: a population-based analysis..
32.
2014
-
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States..
32.
2014
-
The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder..
32.
2014
-
Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder..
32.
2014
-
Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma..
32.
2013
-
High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy..
32.
2013
-
Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?.
32.
2013
-
Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models..
32.
2013
-
Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death..
32.
2013
-
Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy..
31.
2012
-
Indications for and anatomical extent of pelvic lymph node dissection for prostate cancer: practice patterns of uro-oncologists in North America..
31.
2012
-
Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma..
31.
2011
-
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer..
31.
2011
-
Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells..
31.
2011
-
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer..
31.
2011
-
RET protein expression in papillary renal cell carcinoma..
30.
2011
-
Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer..
29.
2010
-
Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?.
29.
2010
-
The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy..
29.
2009
-
Critical elements in fellowship training..
27.
2009
-
Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?.
29.
2008
-
A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate..
27.
2008
-
Medical care cost of patients with prostate cancer..
23.
2005
-
Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors..
21.
2003
-
Mode of presentation of renal cell carcinoma provides prognostic information..
7.
2002
-
Cytokine therapy in renal cell cancer..
5.
2000
-
Carcinoid tumor of the kidney. The use of somatostatin receptor scintigraphy in diagnosis and management..
5.
2000
-
Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostate..
4.
1998
-
Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer..
3.
1997
-
Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladder..
1.
1995
-
The new era of precision urobiome: RE: "Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study" by Chipollini et al.
2020
-
A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy..
33.
2015
-
A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval..
33.
2015
-
A medical oncologist's perspective on the treatment of patients with genitourinary malignancies..
27.
2009
-
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer.
2021
-
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer.
2021
-
A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges.
2021
-
Introduction to "Molecular drivers of prostate cancer development, progression, and resistance to therapy".
2018
-
A multidisciplinary approach for the management of earlier stage renal cell carcinoma.
2018
-
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
2016
-
Salvage high-dose chemotherapy for germ cell tumors.
2015
-
Enzalutamide: Development from bench to bedside.
2015
-
Biomarker development in the context of urologic cancers.
2015
-
Reprint of: The prostate cancer genome: Perspectives and potential.
2015
-
Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma.
2014
-
Prostate cancer biomarkers: an update.
2014
-
The prostate cancer genome: perspectives and potential.
2013
-
Prostate-specific membrane antigen-based imaging.
2012
-
Environmental toxicology of testicular cancer.
2012
-
Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research.
2012
-
Optimal timing of radical cystectomy for patients with T1 bladder cancer.
2009
-
Optimizing outcomes at every stage of bladder cancer: do we practice it?
2009
-
Laparoscopic radical prostatectomy: contemporary comparison with open surgery.
2007
-
The use and abuse of data: nomograms and talking to patients about clinical medicine.
2007
-
A new era in the treatment of urothelial carcinoma.
2023
-
Antibody-drug conjugates for urothelial carcinoma.
2023
-
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints.
2021
-
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?
2021
-
Inguinal lymph node dissection in the era of minimally invasive surgical technology.
2020
-
Role of lymph node dissection in renal cell cancer.
2019
-
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
2017
-
Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer.
2015
-
Salvage therapies after radiation therapy.
2012
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)